FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Biotech Enterprise Capital Monitor – USA 07/2022”.
The Monitor is a month-to-month revealed overview of enterprise capital developments within the US-Biotech sector.
As of the top of July 2022, we determine the next present VC developments within the US-Biotech sector:
- In 2022, total Biotech funding within the USA has reached USD 20,260m thus far
- The highest 5 offers exceed USD 340m every, largest transaction amounted to USD 3,000m in Altos Labs
- ARCH Enterprise Companions (USA) is main the High 5 Buyers (by deal quantity), adopted by 8VC (USA) and Catalio Capital Administration (USA)
- Oncology dominates as the highest indication
To entry the complete report, please click on right here.
By Dr. Mathias Schott, Sebastian Sommer and Johannes Hyperlink